The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 20, 2018
Filed:
Mar. 15, 2014
Applicant:
Sutter West Bay Hospitals, San Francisco, CA (US);
Inventors:
Mohammed Kashani-Sabet, San Francisco, CA (US);
Altaf A. Dar, San Bruno, CA (US);
Assignee:
SUTTER WEST BAY HOSPITALS, San Francisco, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/68 (2006.01); A61K 45/00 (2006.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01); A61K 48/00 (2006.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01); A61K 31/7105 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61K 48/00 (2013.01); C12N 15/113 (2013.01); G01N 33/5743 (2013.01); G01N 33/57407 (2013.01); G01N 33/6872 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01);
Abstract
The disclosure provides methods for predicting and/or determining whether a subject has cancer based on the level of expression of BPTF. The disclosure also provides methods for determining whether a cancer in a subject is progressing or regressing based upon the change of expression levels of BPTF between two time points. The disclosure further provides methods to treat a subject with a cancer by administering a polynucleotide comprising an inhibitory BPTF nucleic acid and/or an agent that inhibits the expression or activity of BPTF.